LPL Financial LLC Boosts Holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

LPL Financial LLC increased its position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 113.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,031 shares of the biopharmaceutical company’s stock after purchasing an additional 16,498 shares during the period. LPL Financial LLC’s holdings in Sangamo Therapeutics were worth $32,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. E Fund Management Co. Ltd. bought a new position in shares of Sangamo Therapeutics in the fourth quarter worth approximately $25,000. PNC Financial Services Group Inc. lifted its position in Sangamo Therapeutics by 2,319.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 26,078 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 25,000 shares in the last quarter. Commonwealth Equity Services LLC boosted its stake in Sangamo Therapeutics by 40.1% during the 4th quarter. Commonwealth Equity Services LLC now owns 95,501 shares of the biopharmaceutical company’s stock valued at $97,000 after purchasing an additional 27,353 shares during the last quarter. SBI Securities Co. Ltd. purchased a new stake in Sangamo Therapeutics during the 4th quarter valued at $28,000. Finally, Shelton Wealth Management LLC bought a new stake in shares of Sangamo Therapeutics in the 4th quarter worth $29,000. 56.93% of the stock is owned by hedge funds and other institutional investors.

Sangamo Therapeutics Stock Down 4.0 %

Shares of NASDAQ:SGMO opened at $0.74 on Friday. The firm’s 50 day moving average price is $0.81 and its 200-day moving average price is $1.37. The stock has a market capitalization of $166.56 million, a PE ratio of -0.99 and a beta of 1.57. Sangamo Therapeutics, Inc. has a twelve month low of $0.30 and a twelve month high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.02). Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The business had revenue of $7.55 million during the quarter, compared to the consensus estimate of $11.70 million. Analysts expect that Sangamo Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on SGMO. Truist Financial dropped their price objective on Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, January 23rd. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Sangamo Therapeutics in a research note on Monday, April 7th. Finally, Royal Bank of Canada restated a “sector perform” rating and set a $2.00 price objective on shares of Sangamo Therapeutics in a research report on Tuesday, March 18th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $5.17.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.